OBJECTIVES/HYPOTHESIS: To examine the level of expression of galectin-3 in relation to neoplastic progression of hypopharyngeal squamous cell carcinomas (HSCCs) and laryngeal squamous cell carcinomas (LSCCs). STUDY DESIGN: Retrospective study. METHODS: Using a polyclonal antibody against galectin-3 without cross-reactivity to other galectins, we analyzed the presence of galectin-3 using quantitative immunohistochemistry in i) a series of 79 HSCCs compared with 16 normal epithelia, 20 low-grade dysplasia (Low_D) and 25 high-grade dysplasia (High_D) and in ii) a series of 58 LSCCs compared with 34 normal epithelia, 12 Low_D, and 18 High_D. In parallel, galectin-3 expression was studied using Western blotting on a series of 19 fresh biopsies from patients presenting a head and neck tumor. RESULTS: Western blotting excluded a notable degree of proteolytic truncation of galectin-3 in situ. Immunohistochemical galectin-3 positivity expressed as percentage of cells was significantly higher in LSCCs and HSCCs than in Low_D (P = .01) or High_D (P = .0002), respectively. Increased expression of galectin-3 in HSCCs was accompanied by a shift from the cytoplasmic compartment to the nucleus (P = .007). In intertumor-type comparison, laryngeal carcinomas presented nuclear presence of galectin-3 only rarely (1 of 58 cases in laryngeal cancer vs. 27 of 79 cases in hypopharyngeal cancer, P = .00006) and a comparatively low labeling index (P < 10(-6)). CONCLUSIONS: Our data reveal an association between level of presence of galectin-3 and neoplastic progression of HSCCs and LSCCs.
OBJECTIVES/HYPOTHESIS: To examine the level of expression of galectin-3 in relation to neoplastic progression of hypopharyngeal squamous cell carcinomas (HSCCs) and laryngeal squamous cell carcinomas (LSCCs). STUDY DESIGN: Retrospective study. METHODS: Using a polyclonal antibody against galectin-3 without cross-reactivity to other galectins, we analyzed the presence of galectin-3 using quantitative immunohistochemistry in i) a series of 79 HSCCs compared with 16 normal epithelia, 20 low-grade dysplasia (Low_D) and 25 high-grade dysplasia (High_D) and in ii) a series of 58 LSCCs compared with 34 normal epithelia, 12 Low_D, and 18 High_D. In parallel, galectin-3 expression was studied using Western blotting on a series of 19 fresh biopsies from patients presenting a head and neck tumor. RESULTS: Western blotting excluded a notable degree of proteolytic truncation of galectin-3 in situ. Immunohistochemical galectin-3 positivity expressed as percentage of cells was significantly higher in LSCCs and HSCCs than in Low_D (P = .01) or High_D (P = .0002), respectively. Increased expression of galectin-3 in HSCCs was accompanied by a shift from the cytoplasmic compartment to the nucleus (P = .007). In intertumor-type comparison, laryngeal carcinomas presented nuclear presence of galectin-3 only rarely (1 of 58 cases in laryngeal cancer vs. 27 of 79 cases in hypopharyngeal cancer, P = .00006) and a comparatively low labeling index (P < 10(-6)). CONCLUSIONS: Our data reveal an association between level of presence of galectin-3 and neoplastic progression of HSCCs and LSCCs.
Authors: Erin C Tracy; Mary J Bowman; Ravindra K Pandey; Barbara W Henderson; Heinz Baumann Journal: Photochem Photobiol Date: 2011-10-03 Impact factor: 3.421
Authors: Paola Quattroni; Yanwen Li; Davide Lucchesi; Sebastian Lucas; Derek W Hood; Martin Herrmann; Hans-Joachim Gabius; Christoph M Tang; Rachel M Exley Journal: Cell Microbiol Date: 2012-08-12 Impact factor: 3.715
Authors: Yunxia Wan; Xi Zhang; Kai Dun Tang; Tony Blick; Liz Kenny; Erik W Thompson; Chamindie Punyadeera Journal: Mol Biol Rep Date: 2021-05-21 Impact factor: 2.316
Authors: Peter Gál; Tomáš Vasilenko; Martina Kostelníková; Ján Jakubco; Ivan Kovác; František Sabol; Sabine André; Herbert Kaltner; Hans-Joachim Gabius; Karel Smetana Journal: Acta Histochem Cytochem Date: 2011-08-10 Impact factor: 1.938
Authors: Prasun Guha; Gargi Bandyopadhyaya; Swamy K Polumuri; Saranya Chumsri; Padmaja Gade; Dhananjaya V Kalvakolanu; Hafiz Ahmed Journal: Breast Cancer Res Treat Date: 2014-03-26 Impact factor: 4.624